Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of DW6014 vs Loose Empagliflozin/Metformin in Healthy Adults
NCT05823870Phase 1Completed
- Sponsor
- Dongwha Pharmaceutical Co., Ltd.
- Start
- Feb 2023
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of DW6014 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Dongwha Pharmaceutical Co., Ltd. Primary endpoints: Area Under the Curve from time 0 to last measurable concentration at 48 hours and Maximum Plasma Concentration at 48 hours. Started Feb 2023; status: completed.
02
Drugs
DW6014
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05823870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05823870.